Development of a point-of-care assay system for measurement of presepsin (sCD14-ST)

Bone, 1992, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine, Chest, 101, 1644, 10.1378/chest.101.6.1644 Battleman, 2002, Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia, Arch Intern Med, 162, 682, 10.1001/archinte.162.6.682 Kumar, 2006, Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, Crit Care Med, 34, 1589, 10.1097/01.CCM.0000217961.75225.E9 Rivers, 2001, Early goal-directed therapy in the treatment of severe sepsis and septic shock, N Engl J Med, 345, 1368, 10.1056/NEJMoa010307 Rangel-Frausto, 1995, The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study, JAMA, 273, 117, 10.1001/jama.1995.03520260039030 Bhatia, 2007, Newer diagnostic tests for bacterial diseases, Indian J Pediatr, 74, 673, 10.1007/s12098-007-0119-6 Herzum, 2008, Inflammatory markers in SIRS, sepsis and septic shock, Curr Med Chem, 15, 581, 10.2174/092986708783769704 Christ-Crain, 2005, Procalcitonin in bacterial infections–hype, hope, more or less?, Swiss Med Wkly, 135, 451 Yaegashi, 2005, Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis, J Infect Chemother, 11, 234, 10.1007/s10156-005-0400-4 Meisner, 1999, Procalcitonin: Erfahrungen mit einer neuen Messgroesse fuer bakterielle Infektionen und systemische Inflammation, J Lab Med, 23, 263 Kojika, 2010, Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA Scores, Medical Postgraduates, 48, 46 Takahashi, 2010, Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring, Medical Postgraduates, 48, 19 Shirakawa, 2011, Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients, Clin Chem Lab Med, 49, 937, 10.1515/CCLM.2011.145 Kurihara, 2008, Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST, Anal Biochem, 375, 144, 10.1016/j.ab.2007.12.030 Furusako S, Shirakawa K, Methods for detecting human low molecular weight CD14. United States patent 2008;US7465547 B2. Furusako S, Shirakawa K, Hirose J. Soluble CD14 antigen. United States patent 2009;US7608684 B2. Bablok, 1983, A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I, J. Clin. Chem. Biochem., 21, 709 CLSI, 2004, Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline, NCCLS document CLSI, 2004, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition, NCCLS document Shozushima, 2011, Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome, J Infect Chemother, 12 Dellinger, 2008, Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008, Crit Care Med, 36, 296, 10.1097/01.CCM.0000298158.12101.41